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Abstract 
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant disorder charac-
terized by the development of benign hamartomas in multiple organs. Most patients with 
TSC exhibit cutaneous manifestations. Methods: We report a 28-year-old patient with multi-
ple pink papules at the proximal nail fold of several toes. Results: Histopathological analysis 
of a biopsy of a papule was consistent with an ungual fibroma. Histopathological analysis of 
a biopsy of an elevated skin-colored plaque at the lower back was diagnostic for a Shagreen 
patch. These findings were consistent with a clinical diagnosis of TSC. This patient was sub-
sequently referred to a multidisciplinary TSC clinic for further screening, which revealed a 
giant cell astrocytoma and multiple subependymal tubers. Annual monitoring was recom-
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mended. The skin lesions were treated with topical rapamycin ointment. Conclusions: Rec-
ognizing dermatological manifestations of TSC is of importance to allow early diagnosis. TSC 
should be considered as a differential diagnosis in the case of ungual fibromas, even in older 
patients. © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by 
mutations in the TSC1 or TSC2 gene [1]. The incidence of TSC is estimated at 1 case per 
6,000 births [2]. TSC is characterized by the development of benign hamartomas that can 
occur in multiple organs, including the brain, heart, lungs, kidneys, and skin [3]. Further-
more, TSC can be associated with neurological manifestations such as epilepsy and learning 
disabilities [4]. Both the spectrum and severity of clinical manifestations of TSC are variable. 
Several manifestations of TSC have an age-dependent onset of expression [5]. As a result, 
clinical evaluation for TSC can be difficult. Early diagnosis of TSC is of importance, consider-
ing that TSC is associated with increased morbidity and mortality [6]. In addition, there is an 
increased risk of malignancy in TSC, primarily in the kidneys, brain, and soft tissues [7]. 
TSC can be diagnosed through genetic identification of a pathological mutation or by 
means of clinical features. In 2012, the diagnostic criteria for TSC were revised and catego-
rized into major and minor features (see Table 1) [3]. A definite diagnosis of TSC can be 
made in the case of 2 major features or 1 major feature with 2 or more minor features. Posi-
tivity of 1 major feature alone or 2 or more minor features is indicative of a possible diagno-
sis of TSC. 
Cutaneous manifestations are common in TSC [8]. In fact, 4 out of 11 major TSC criteria 
and 3 out of 6 minor criteria comprise dermatological features. The majority of patients with 
TSC have 1 or more TSC-related skin lesions [9]. Several dermatological features of TSC often 
present early – within the first months after birth (see Table 2) [10]. Recognizing dermato-
logical manifestations of TSC is therefore of importance to allow early diagnosis [8]. Here, we 
report a case of TSC in which the suspicion of a diagnosis of TSC was based on dermatologi-
cal findings. 
Report 
A 28-year-old male patient was referred to our dermatology outpatient clinic for evalua-
tion of nail lesions. He had growths at the proximal nail fold of several of his toes that were 
present for 2 years. Prior treatment with miconazole cream was unsuccessful in clearing the 
nail lesions. His medical history was significant for asthma, for which he used salbutamol 
and salmeterol/fluticasone inhalation. Furthermore, at the age of 1 year he was diagnosed 
with epilepsy. There was no family history of dermatological or genetic disorders. 
At clinical examination, multiple pink-colored pedunculated papules at the lateral basis 
of the proximal nail fold of digit 1 and 4 of his left foot were noted (see Fig. 1). Further, total 
body skin inspection revealed multiple hypopigmentated maculae at the trunk and a slightly 
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elevated skin-colored plaque at the lower back. At the malar region of the face, several red 
papules were seen. 
Histopathological analysis of a skin biopsy obtained from a papule at the proximal nail 
fold showed hyperkeratosis of the epidermis and thick collagen bundles together with dilat-
ed vessels in the dermis. These findings were consistent with a diagnosis of ungual fibroma, 
also known as a Koenen tumor (see Fig. 1). Histopathological analysis of a skin biopsy of the 
plaque at the lower trunk showed thickened bundles of collagen within the dermis with 
widely spaced, diminished, and fragmented elastic fibers, consistent with a collagenoma (see 
Fig. 2). Based on clinicopathological correlation, a diagnosis of Shagreen patch was made.  
Taken together, these findings were consistent with a clinical diagnosis of TSC. This pa-
tient was subsequently referred to a specialized TSC clinic for adult patients at the Universi-
ty Medical Center Utrecht (Utrecht, The Netherlands) for further screening and manage-
ment. MRI of the cerebrum showed a giant cell astrocytoma and multiple subependymal 
tubers. MRI of the kidneys showed multiple small cysts; there were no angiomyolipomas. CT 
of the thorax revealed lipomas in the cardiac ventricle wall. Ophthalmic evaluation was 
without abnormalities.  
Given the abnormalities in the cerebrum, yearly follow-up was advised. The skin and 
nail lesions were treated with topical rapamycin (sirolimus) 0.01% ointment, which is a 
mammalian target of rapamycin (mTOR) inhibitor. 
Discussion 
TSC is a genetic multi-organ disease with a highly variable disease expression. Here, we 
report a case of a 28-year-old male patient with a medical history of epilepsy in which the 
diagnosis of TSC was determined clinically on the presence of ungual fibromas and a Sha-
green patch. 
This report has several learning points. First, this case is an example of an age-related 
expression of the clinical manifestations of TSC. The ungual fibromas, which in this case 
were the presenting sign for the diagnosis of TSC, had an onset at age 26 years. This is in line 
with previous findings that ungual fibromas present during adolescence (see Table 2) [9, 
11]. Therefore, a possible diagnosis of TSC should be considered when patients present with 
skin lesions suggestive for TSC, even at an older age. Second, TSC should be considered as a 
differential diagnosis in the case of ungual fibromas, especially with a medical history of 
neurological symptoms such as epilepsy. Third, full body skin examination including the 
nails and oral cavity is of importance when a diagnosis of TSC is suspected in order to assess 
other potential TSC-related cutaneous manifestations [10]. Fourth, de novo mutations, like 
in this case, occur in about 80% of TSC patients [12]. Therefore, in most cases there is no 
family history of TSC. 
Given the potential multi-organ manifestations of TSC, the management and follow-up of 
TSC requires a multidisciplinary approach. We referred our patient to a specialized TSC clin-
ic for adult patients. There, annual follow-up will be performed according to current recom-
mendations [13]. 
Treatment with sirolimus ointment, a topical mTOR inhibitor, was initiated to treat the 
cutaneous lesions. To date, only case series are available on the use of topical sirolimus for 
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TSC-related skin lesions [14, 15]. In randomized, placebo-controlled trials with oral everoli-
mus, an mTOR inhibitor, positive effects were noted on the clearance of skin lesions [16]. 
Other treatment options for cutaneous TSC lesions include surgery and laser therapy [8]. 
In conclusion, cutaneous features are common in TSC and may be a presenting sign for 
the diagnosis. Recognizing dermatological manifestations of TSC is of importance to allow 
early diagnosis. 
Statement of Ethics 
Informed consent for publishing this case was obtained from the patient. 
Disclosure Statement 
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Fig. 1. a, b Clinical photographs of ungual fibromas (arrows). c Histopathological analysis of a skin biopsy 
obtained from a papule at the proximal nail fold, consistent with an ungual fibroma. 
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Fig. 2. a Clinical photograph of a Shagreen patch (arrow). b Histopathological analysis of a skin biopsy 
obtained from a plaque at the lower trunk, consistent with a Shagreen patch. 
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Table 1. Revised clinical diagnostic criteria for TSC, according to the 2012 International Tuberous Sclerosis 
Complex Consensus Conference [3] 
 
 
Major criteria 
Hypomelanotic macules (≥3, at least 5-mm diameter) 
Angiofibromas (≥3) or fibrous cephalic plaque 
Ungual fibromas (≥2) 
Shagreen patch 
Multiple retinal hamartomas 
Cortical dysplasias 
Subependymal nodules 
Subependymal giant cell astrocytoma 
Cardiac rhabdomyoma 
Lymphangioleiomyomatosis 
Angiomyolipomas 
  Minor criteria 
“Confetti” skin lesions 
Dental enamel pits (>3) 
Intraoral fibromas (≥2) 
Retinal achromic patch 
Multiple renal cysts 
Nonrenal hamartomas 
 
 
 
 
Table 2. Dermatological manifestations of TSC 
   
   
Feature Prevalence Age at onset 
   
   
Hypomelanotic macules Up to 90% 00 years 
Angiofibromas 75% 02–5 years 
Ungual fibromas 20–80% 20–30 years 
Shagreen patch 50% 00–10 years 
“Confetti” skin lesions Up to 60% 00–10 years 
   
   
 
 
 
D
ow
nl
oa
de
d 
by
: 
Er
as
m
us
 U
ni
v.
of
 R
ot
te
rd
am
 M
ed
ica
l L
ib
ra
ry
   
   
   
   
  
13
0.
11
5.
13
3.
25
1 
- 5
/1
6/
20
17
 2
:3
8:
00
 P
M
